Literature DB >> 15565298

Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain.

Harald Hampel1, Andreas Haslinger, Michael Scheloske, Frank Padberg, Petra Fischer, Josef Unger, Stefan Johannes Teipel, Michaela Neumann, Carlyn Rosenberg, Rusti Oshida, Christine Hulette, Dieter Pongratz, Michael Ewers, H A Kretzschmar, Hans-Jürgen Möller.   

Abstract

Involvement of the interleukin-6 receptor complex (IL-6RC) in neuroregulatory and immunological processes of the brain and particularly in Alzheimer's disease (AD) has been hypothesized. The functionally active IL-6RC consists of the cytokine IL-6, which acts through the ligand binding IL-6R and the signal transducing gp130. Using a new immunocytochemical protocol on rapid autopsy cryostat brain sections we studied the expression of the IL-6RC in Braak IV-V staged AD patients compared to normal age-matched controls (HC) across five different cortical regions. Inter-rater reliability of the method was high. The "baseline" expression in normal human brain was determined for IL-6,IL-6R and gp130 in all cortical regions. In normal tissue IL-6 expression was lower in parietal cortex. Higher IL-6R expression was shown in frontal, occipital and parietal cortex, lower expression in temporal cortex and cerebellum. In AD IL-6 expression levels were generally increased in parietal cortex and decreased in occipital cortex compared to controls. IL-6R expression levels were strongly increased in AD frontal and occipital cortex and decreased in temporal cortex and cerebellum. Our findings indicate an altered cortical immunoreactivity pattern of the functional IL-6RC in AD supporting the hypothesis of a disease-related role of IL-6 in AD pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15565298     DOI: 10.1007/s00406-004-0558-2

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  73 in total

Review 1.  Molecular basis underlying functional pleiotropy of cytokines and growth factors.

Authors:  T Hirano
Journal:  Biochem Biophys Res Commun       Date:  1999-07-05       Impact factor: 3.575

Review 2.  Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

Authors:  Richard A Frank; Douglas Galasko; Harald Hampel; John Hardy; Mony J de Leon; Pankaj D Mehta; Joseph Rogers; Eric Siemers; John Q Trojanowski
Journal:  Neurobiol Aging       Date:  2003 Jul-Aug       Impact factor: 4.673

3.  Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease.

Authors:  S Du Yan; H Zhu; J Fu; S F Yan; A Roher; W W Tourtellotte; T Rajavashisth; X Chen; G C Godman; D Stern; A M Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

4.  Cerebrospinal fluid interleukin-6 activity in HIV infection and inflammatory and noninflammatory diseases of the nervous system.

Authors:  M A Laurenzi; A Sidén; M A Persson; G Norkrans; L Hagberg; F Chiodi
Journal:  Clin Immunol Immunopathol       Date:  1990-11

5.  Impaired neuroglial activation in interleukin-6 deficient mice.

Authors:  M A Klein; J C Möller; L L Jones; H Bluethmann; G W Kreutzberg; G Raivich
Journal:  Glia       Date:  1997-03       Impact factor: 7.452

6.  Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices.

Authors:  J Bauer; S Strauss; U Schreiter-Gasser; U Ganter; P Schlegel; I Witt; B Yolk; M Berger
Journal:  FEBS Lett       Date:  1991-07-08       Impact factor: 4.124

7.  Experimental axonal injury triggers interleukin-6 mRNA, protein synthesis and release into cerebrospinal fluid.

Authors:  V H Hans; T Kossmann; P M Lenzlinger; R Probstmeier; H G Imhof; O Trentz; M C Morganti-Kossmann
Journal:  J Cereb Blood Flow Metab       Date:  1999-02       Impact factor: 6.200

8.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.

Authors:  I L Campbell; C R Abraham; E Masliah; P Kemper; J D Inglis; M B Oldstone; L Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

9.  Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.

Authors:  M Narazaki; K Yasukawa; T Saito; Y Ohsugi; H Fukui; Y Koishihara; G D Yancopoulos; T Taga; T Kishimoto
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

10.  In vitro binding of ciliary neurotrophic factor to its receptors: evidence for the formation of an IL-6-type hexameric complex.

Authors:  A De Serio; R Graziani; R Laufer; G Ciliberto; G Paonessa
Journal:  J Mol Biol       Date:  1995-12-15       Impact factor: 5.469

View more
  26 in total

1.  Trajectories of peripheral interleukin-6, structure of the hippocampus, and cognitive impairment over 14 years in older adults.

Authors:  Andrea L Metti; Howard Aizenstein; Kristine Yaffe; Robert M Boudreau; Anne Newman; Lenore Launer; Peter J Gianaros; Oscar L Lopez; Judith Saxton; Diane G Ives; Stephen Kritchevsky; Abbe N Vallejo; Caterina Rosano
Journal:  Neurobiol Aging       Date:  2015-07-28       Impact factor: 4.673

2.  Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia.

Authors:  Chie Yasutake; Kenji Kuroda; Toshio Yanagawa; Takehiko Okamura; Hiroshi Yoneda
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-06-16       Impact factor: 5.270

Review 3.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

Review 4.  Interleukin 6 and cognitive dysfunction.

Authors:  Isabel Trapero; Omar Cauli
Journal:  Metab Brain Dis       Date:  2014-04-30       Impact factor: 3.584

5.  Characterisation of amyloid-induced inflammatory responses in the rat retina.

Authors:  D R Howlett; S T Bate; S Collier; A Lawman; T Chapman; T Ashmeade; I Marshall; P J B Anderson; K L Philpott; J C Richardson; C J Hille
Journal:  Exp Brain Res       Date:  2011-08-18       Impact factor: 1.972

6.  IL-6 regulation of synaptic function in the CNS.

Authors:  Donna L Gruol
Journal:  Neuropharmacology       Date:  2014-11-22       Impact factor: 5.250

7.  ATM inhibition prevents interleukin-6 from contributing to the proliferation of glioblastoma cells after ionizing radiation.

Authors:  Yi Chieh Lim; Hazel Quek; Carolin Offenhäuser; Shazrul Fazry; Andrew Boyd; Martin Lavin; Tara Roberts; Bryan Day
Journal:  J Neurooncol       Date:  2018-03-21       Impact factor: 4.130

Review 8.  Genetic predisposition to inflammation: a new risk factor of Alzheimer's disease.

Authors:  Ying Wan; Gang Wang; Sheng-Di Chen
Journal:  Neurosci Bull       Date:  2008-10       Impact factor: 5.203

9.  Soluble interleukin-6 receptor levels and risk of dementia: one more signpost on a long road ahead.

Authors:  Madhav Thambisetty; Luigi Ferrucci
Journal:  J Am Geriatr Soc       Date:  2014-04       Impact factor: 5.562

10.  Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease.

Authors:  Onofre Combarros; Cornelia M van Duijn; Naomi Hammond; Olivia Belbin; Alejandro Arias-Vásquez; Mario Cortina-Borja; Michael G Lehmann; Yurii S Aulchenko; Maaike Schuur; Heike Kölsch; Reinhard Heun; Gordon K Wilcock; Kristelle Brown; Patrick G Kehoe; Rachel Harrison; Eliecer Coto; Victoria Alvarez; Panos Deloukas; Ignacio Mateo; Rhian Gwilliam; Kevin Morgan; Donald R Warden; A David Smith; Donald J Lehmann
Journal:  J Neuroinflammation       Date:  2009-08-23       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.